treatment is very effective at stopping visual loss, the initial visual defects as measured on SAP are irreversible. Therefore, early detection, before substantial damage has taken place, is an important aspect of glaucoma management. Furthermore, some studies suggest that substantial ganglion cell damage can take place prior to detectable defects on SAP. 1, 2 There has been much interest, therefore, in ways of detecting visual changes before irreversible damage occurs.
To this end, electrophysiological testing has been considered as a possible means of early detection. The multifocal visual evoked potential (mfVEP) is one such promising test. With this technique, multiple responses correlating to specific localized regions of the visual field can be tested simultaneously. 3 Multiple studies have shown the relatively high sensitivity of the mfVEP in detecting glaucomatous damage. e.g. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, nearly all of this work has been based on amplitude measures of the mfVEP. Relatively little has been reported about the latency of mfVEP responses in glaucoma patients. 14 There have been a number of studies with conventional visual evoked potentials (cVEP) showing large latency delays, on the order of 20 ms, in glaucoma patients. [15] [16] [17] [18] [19] A recent study 19 reported that the cVEP latency had a 100% sensitivity and specificity in distinguishing normal controls from patients with open-angle glaucoma. Further, the cVEP latency has been used as a marker of reversible ganglion cell damage in trials of neuroprotective agents for the treatment of glaucoma. 20 The implication is that latency can be used as a measure of early glaucomatous damage prior to retinal ganglion cell death.
A potential problem with the cVEP is that it represents the weighted sum of many local responses. Thus, the technique may obscure delays in local responses. These delays in latency should be seen more easily with the mfVEP. However, a report, in abstract form, suggested rather small latency changes with glaucomatous damage. 14 
mfVEP recording
Three signal channels were recorded simultaneously with gold cup electrodes. The ground and reference electrodes were placed on the forehead and inion, respectively. The three active electrodes were placed 4 cm above the inion (midline channel), and 4 cm on either side of and 1 cm above the inion (lateral channels). All three channels were filtered with a low and high frequency cutoff of 3 Hz and 100 Hz (Grass Instruments preamplifier P511J, Quincy, Mass.).
The resistance was less than 5k for all subjects. Four monocular, 7 minute recordings were obtained, two for each eye (ABBA order). The mfVEP responses were exported from the VERIS 4.3 software from EDI (San Mateo, CA). See Hood et al. 21 and Hood and Greenstein 10 for more details.
mfVEP analysis
The exported mfVEP records were processed using custom software written in MATLAB (Mathworks Inc., Natick, MA) and an array of best channel responses derived as previously described. 10, 21, 22 The mfVEP best channel responses for a NTG patient are shown as the records in color in Fig. 1B .
Relative monocular latency and the interocular difference in latency were determined at each of the 60 locations and compared with a normative set using computerized techniques previously described. 23, 24 Briefly, relative monocular latencies were determined by shifting the subject's best channel response along the time axis to give the maximal overlap (cross-correlation) with a template trace determined from a normative group. The normative group consisted of 100 individuals whose characteristics have been previously described. 25 The amount of shift was the relative monocular latency, as compared to the norms, in milliseconds. Only the more affected eye, based on 24-2 Humphrey visual field (HVF) mean deviation, was included in the monocular latency analysis. The difference in interocular latencies at each location was determined by shifting the right eye response along the time axis to overlap maximally (best cross-correlation)
with the left eye. The amount of shift was the interocular latency difference, with a positive value signifying that the response of the more affected eye was slower than that of the less affected eye. 
RESULTS
Examples of mfVEP responses and latency probability plots for a typical NTG patient are shown in Fig. 1 . Figure 1B shows the mfVEP responses from both eyes (red: OS; blue: OD). As indicated by the colored circles in Figs. 1C and D, 14 and 10 locations were significantly delayed on the interocular and monocular probability plots, respectively. However, these delays were relatively small. As will be seen below, the results for this patient were typical.
Average Latency
The monocular analysis provides the most direct comparison to previous cVEP data. Each symbol in Figs percentile for the norms. Using the 95 percentile of the norms as a criterion, the sensitivity and specificity were 30% and 87%, respectively ( Table 2 ). The interocular analysis does a slightly better job of distinguishing among the patients and The latency data from Fig. 2 for the three groups of subjects are shown as a function of MD in Fig. 3 . For the monocular data (Fig. 3A ) the latency and MD values are for the more affected eye, while for the interocular data (Fig. 3B ) the latency is plotted against the difference between the MDs of the more (poorer MD) and less affected eyes. There was no relationship between either the monocular (panel A) or interocular latency (panel B) and MD.
Percent Delayed Traces
To take advantage of the localizing ability of the mfVEP, the latency probability plots (Fig.   1C,D) were analyzed. For each subject the percentage of significantly delayed responses was determined by dividing the number of significant (colored) locations in Fig. 1C,D by the total number of responses that met criteria for measurement (i.e. 60 minus the number of gray locations). Table 1 as a criterion, the sensitivity and specificity were 20% and 91%, respectively (Table 2) . For the interocular analysis, 32% (16 patients: 9 HTG and 7 NTG) fell above the range of control values and 38% (19 patients: 11 HTG and 8 NTG) fell above the 95 percentile for the norms. The sensitivity and specificity were 38% and 98%, respectively.
DISCUSSION
The identification of glaucoma patients with abnormal latencies could open the possibility of neuroprotection of unhealthy retinal ganglion cells. In this regard, reports of substantial delays in the conentional VEP (cVEP) encouraged us to assess delays with the locally more sensitive mfVEP technique. The delays in the glaucoma group were modest, on average less than 4 ms, when compared to the control group, and involved fewer than 40% of the patients.
Our results provide a marked contrast to those recently reported by Parisi et al. 19 . In that study, all 84 patients with OAG had cVEP latencies that were longer than the longest latency found among the 80 normal control subjects. Further, the mean latency of the OAG group was 27.8 ms longer than that of the control group. The monocular mean latency analysis of our HTG group provides the most direct comparison to their study. Our HTG group had, on average, an increase in latency of only 5.3 ms as compared to the normative group and only 3.6 ms compared to the control group. Further, there was considerable overlap with the control and normative groups with only one patient's value falling above the control group range. Using the 95 percentile of the normative data as a definition of abnormal latency resulted in a sensitivity and specificity of 30 and 87%, respectively, values far from the 100% sensitivity and specificity reported for the cVEP by Parisi et al 19 .
For our patients, the interocular test for mean latency does a little better. Using the 95 percentile of the norms, the sensitivity and specificity were 36 and 100%, respectively. Using the percent of points in the field with abnormal latencies yielded similar results with again the interocular comparison providing better discrimination than the monocular comparison.
The reasons for these discrepancies with the Parisi et al study are not entirely clear. While the OAG patients in their study had, on average, more severe field losses than our HTG group, their results were substantially the same for their patients with MDs in the same range (better than -8 dB) as ours. In addition, other patient characteristics (e.g. age) cannot explain the difference in results. On the other hand, the mfVEP and cVEP techniques differ in both the stimulus used and the analysis employed. Further, the evidence suggests that the mfVEP has less of a post V1 contribution, than does the cVEP. Theoretically it is possible the delays are introduced beyond V1. However, before invoking such speculative explanations, recordings of both cVEP and mfVEP from the same group of patients need to be made. We are completing such a study.
In summary, in a group of patients with glaucoma and mild to moderate visual field loss, the delays in the mfVEP were modest. On average the delays were a few milliseconds and they rarely exceeded 10 ms. On the other hand, up to 40% of these patients may have abnormal latencies and these are best detected with an interocular analysis. Before a decision is made to use either the mfVEP or cVEP in neuroprotection trials the discrepancy between the mfVEP and cVEP needs to be understood. A.
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